21 November 2025

An early-stage trial taking place within the Cambridge BRC aims to improve treatment for people with late-stage pancreatic cancer, a challenging cancer that is often diagnosed late, when few treatment options are available.

Clinicians at Addenbrooke’s Hospital highlighted the trial on world pancreatic cancer day (20 Nov). Pancreatic cancer is the tenth most common cancer in the UK. Around 10,000 people are diagnosed each year. Of these, at least 40 percent are diagnosed when the cancer has already spread to other parts of the body (stage 4).

The CRISTAL-APC trial is being led from Cambridge University Hospitals NHS Foundation Trust (CUH) and the University of Cambridge, supported by the NIHR Cambridge Clinical Research Facility.  It aims to improve treatment for people with stage 4 pancreatic cancer by reducing side effects without reducing efficacy. The trial will combine chemotherapy with a drug known as VP-002.

The life expectancy for people diagnosed with stage 4 pancreatic cancer is less than a year and, when diagnosed, many people are already too unwell to benefit from existing treatments. Where treatment is possible, the leading option is intensive chemotherapy that often comes with side effects and little, if any, improvements in quality of life.

Chief investigator of the trial, Dr Bristi Basu, hopes that the combination of VP-002 and chemotherapy will be more effective against the cancer, while causing less harm to patients.

VP-002 has been developed based on research performed in Cambridge led by Dr Tony Wu and Dr Michael Gill at the Cancer Research UK Cambridge Institute, University of Cambridge.

As cancers grow, they make changes to their surroundings. These changes help the cancer to keep growing and protect it against treatment. The research in Cambridge showed that a key protein in this process is the CCR1 receptor. VP-002 shuts down the CCR1 receptor, making it harder for the cancer to grow and weakening its defenses.

By using VP-002 to weaken the cancer, doctors hope to be able to use a lower dose of chemotherapy. For patients, this could mean fewer side effects, while still being just as effective at treating cancer.

In total, the trial aims to include 120 patients across 15 hospitals. It will run in two phases. The first will look at different doses of VP-002 and chemotherapy to identify which is the safest and most effective combination. In the second phase, the combination of chemotherapy plus VP-002 will be compared against the current standard treatment of chemotherapy alone.

If successful, larger studies will be needed to prove whether VP-002 should become a standard treatment for late-stage pancreatic cancer.

Dr Basu, who also co-leads the Pancreatic Cancer Programme at the Cancer Research UK Cambridge Centre, notes that the treatment is not expected to be a cure, but that it could slow disease progression and give people more quality time with their family and friends.

VP-002 is being developed by Cycle Pharmaceuticals, who have also funded the trial. The trial is being run from the National Institute of Health & Care Research (NIHR) Cambridge Clinical Research Facility (CRF) and the NIHR Cambridge Clinical Trials Unit a UK clinical research collaboration (UKCRC) registered academic clinical trials unit.

Dr Basu, (pictured below left) an honorary consultant medical oncologist at CUH and clinical senior research associate in the Department of Oncology, University of Cambridge, said: